Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
Status:
Completed
Trial end date:
2019-11-18
Target enrollment:
Participant gender:
Summary
This phase Ib, open-label, single-center, non-randomized clinical trial will evaluate the
toxicity and efficacy of metformin and chloroquine in isocitrate dehydrogenase 1/2-mutated
(IDH1/2MT) patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)